OUR JOURNEY

Keith is a scientist/entrepreneur in the for-profit and non-profit biomedical space, and has co-founded more than a dozen companies. He was a founder and Executive Director of the i2b2 tranSMART Foundation, he founded the Systems Biology program at CHDI Foundation, and he was Chief Commercial Officer at Curoverse. He has also been the founder and CEO or CSO of biotechnology companies in the areas of biomedical computing, artificial intelligence, systems biology, and genomics. He has spent his career in the pharmaceutical (Merck and Bayer) and biotechnology (Gene Logic, Viaken, Genstruct/Selventa) industries, and in the non-profit (CHDI, tranSMART, i2b2 tranSMART Foundations) space.

Steve is an experienced finance and strategy executive, and has served as VP of Finance and/or CFO for numerous public and private companies including PricewaterhouseCoopers, Avid Technology, Panviva, Abiomed, Punchey, Inc.,  and TechCXO. He also has extensive experience with non-profit foundations, and serves on the Finance Committee of the Autism Foundation.

Scott is an experienced healthcare technology executive with deep roots in product development and hospital operations. He has extensive experience having served in leadership roles in Provider and Payor organizations and worked closely with the Life Sciences industry to responsibly monetize patient data for research and clinical trials. He served as the Chief Technology Officer for Optum Analytics (the leader in RWE), CTO for Cancer Treatment Centers of America, and was the CTO for PHEMI Systems. Scott also serve as a company commander in the US Army and Reserves.

Deb’s career has been focused at the intersection of basic and applied health sciences research, bioinformatics, computational biology, and the business of science. She has deep experience commercializing diverse products and services at early-stage start-up companies in the health science ecosystem. Deb has had senior leadership positions at Cellomics, Inc, RedPath Integrated Pathology, Theranostics Health, and Cellumen, Inc. These commercialization efforts include product development, marketing, market and business development and the development, support and execution of B2B sales strategies. Deb also has extensive experience managing the development of diverse database and analytics tools to support drug discovery, AI-based drug discovery, genomics research, biospecimen research, and serological science research.

As the Director of Operations at Axiomedix, Tish brings her experience with two-sided marketplaces from working with eBay’s Kijij in Canada, Used.ca in Canada and UK, and as a Board member of the International Classified Marketplace Association (ICMA). She has been the Alliance Manager for the Amazon Web Services Partner Network and a Marketing Manager for Microsoft Corporation. Her experience in marketing comes from GROUP360 Worldwide, as the Director of Digital, where she was responsible for developing marketing and eCommerce strategies for Fortune 1000 brands. Tish holds a science degree in health informatics and was formerly the Director of Operations at PHEMI Systems in Canada.

Peter Rice is a highly-experienced bioinformatician and scientific software developer. Peter has been working as a lead developer on tranSMART since the project became open source in 2013, and was the senior tranSMART developer on the European eTRIKS project (€24M IMI project) and leads the tranSMART development efforts with the i2b2-tranSMART Foundation. Peter is the release manager for tranSMART, and is currently responsible for the new tranSMART 19 release. He serves as a member of the tranSMART PMC and he is also the Foundation data content manager responsible for the postgres and oracle schemas and managing a collection of curated public patient datasets. Peter also manages an Axiomedix i2b2/tranSMART server, several tranSMART servers, and is developing an installer for our i2b2 server. Previously Peter was a senior developer with the European Bioinformatics Institute (EBI), Lion Bioscience, the Wellcome Trust Sanger Institute and the European Molecular Biology Laboratory (EMBL). Peter is the lead developer for the open-source EMBOSS suite for molecular sequence analysis.